ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ACAD Acadia Pharmaceuticals Inc

17.05
-0.03 (-0.18%)
After Hours
Last Updated: 22:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Acadia Pharmaceuticals Inc NASDAQ:ACAD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -0.18% 17.05 17.05 17.88 17.5839 17.03 17.44 1,160,279 22:30:00

ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

25/09/2019 9:05pm

Business Wire


Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Acadia Pharmaceuticals Charts.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 3:00 p.m. Eastern Time in New York City.

A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through October 30, 2019.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 ir@acadia-pharm.com

Media Contact: ACADIA Pharmaceuticals Inc. Maurissa Messier (858) 768-6068 media@acadia-pharm.com

1 Year Acadia Pharmaceuticals Chart

1 Year Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock